Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BENJAMIN ORIE HERZBERG

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1861873275
CMS profile
1359383
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$18,408.32

8 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $17,606.00 5
Travel and Lodging $671.32 1
Food and Beverage $131.00 2

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Daiichi Sankyo Inc. $7,421.32 2
Janssen Global Services, LLC $7,050.00 1
Janssen Research & Development, LLC $2,520.00 1
Amgen Inc. $686.00 1
ABBVIE INC. $600.00 1
Genentech USA, Inc. $68.00 1
Eli Lilly and Company $63.00 1

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BENJAMIN ORIE HERZBERG

NPI 1861873275 · CMS profile ID 1359383

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1861873275?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BENJAMIN ORIE HERZBERG, NPI 1861873275, CMS profile ID 1359383. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861873275?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). BENJAMIN ORIE HERZBERG, NPI 1861873275, CMS profile ID 1359383. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861873275?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
BENJAMIN ORIE HERZBERG, NPI 1861873275, CMS profile ID 1359383, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1861873275?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

8 matching records · $18,408.32 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 8 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–8 of 8.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $600.0007/11/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1202040139 CMS
Eli Lilly and Company $63.0006/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186526155 CMS
Genentech USA, Inc. $68.0006/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211498139 CMS
Daiichi Sankyo Inc. $6,750.0005/07/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1197089479 CMS
Daiichi Sankyo Inc. $671.3204/29/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1197087899 CMS
Janssen Global Services, LLC $7,050.0004/14/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1173805341 CMS
Amgen Inc. $686.0001/31/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1226911411 CMS
Janssen Research & Development, LLC $2,520.0001/21/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1173804073 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $106.30 2
PY2023 $970.06 4
PY2024 $4,751.70 5
PY2025 $18,408.32 8

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,023,233.04 218
PY2024 Principal investigator $909,794.38 160
PY2023 Principal investigator $870,048.69 649
PY2022 Principal investigator $8,640.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

160 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,213.70 12/30/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton No dispute reported 06/30/2026 1110842068
Principal investigator 1 Astellas Pharma Inc $236.25 12/18/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599684
Principal investigator 1 Astellas Pharma Inc $5,253.16 12/18/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599688
Principal investigator 1 Astellas Pharma Inc $36,609.59 12/06/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599686
Principal investigator 1 Astellas Pharma Inc $169.38 11/21/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599580
Principal investigator 1 Astellas Pharma Inc $169.38 11/21/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599582
Principal investigator 1 Astellas Pharma Inc $169.38 11/21/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599584
Principal investigator 1 Astellas Pharma Inc $169.38 11/21/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599586
Principal investigator 1 Astellas Pharma Inc $169.38 11/21/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599588
Principal investigator 1 Astellas Pharma Inc $169.38 11/21/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599590
Principal investigator 1 Astellas Pharma Inc $169.38 11/21/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599592
Principal investigator 1 Astellas Pharma Inc $169.38 11/21/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599594
Principal investigator 1 Astellas Pharma Inc $169.38 11/21/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599596
Principal investigator 1 Astellas Pharma Inc $169.38 11/21/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599598
Principal investigator 1 Astellas Pharma Inc $169.38 11/21/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599606
Principal investigator 1 Astellas Pharma Inc $169.38 11/21/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599632
Principal investigator 1 Astellas Pharma Inc $169.38 11/21/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599634
Principal investigator 1 Astellas Pharma Inc $169.38 11/21/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599636
Principal investigator 1 Astellas Pharma Inc $169.38 11/21/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599640
Principal investigator 1 Astellas Pharma Inc $169.38 11/21/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599642
Principal investigator 1 Astellas Pharma Inc $3,297.90 11/13/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599600
Principal investigator 1 Astellas Pharma Inc $1,263.00 11/13/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599602
Principal investigator 1 Astellas Pharma Inc $338.31 11/13/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599604
Principal investigator 1 Astellas Pharma Inc $3,297.90 11/13/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599608
Principal investigator 1 Astellas Pharma Inc $3,297.90 11/13/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599610
Principal investigator 1 Astellas Pharma Inc $405.00 11/13/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599612
Principal investigator 1 Astellas Pharma Inc $3,297.90 11/13/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599614
Principal investigator 1 Astellas Pharma Inc $11,288.93 11/13/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599616
Principal investigator 1 Astellas Pharma Inc $3,297.90 11/13/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599618
Principal investigator 1 Astellas Pharma Inc $1,620.00 11/13/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599620
Principal investigator 1 Astellas Pharma Inc $11,288.93 11/13/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599622
Principal investigator 1 Astellas Pharma Inc $11,288.93 11/13/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599624
Principal investigator 1 Astellas Pharma Inc $11,288.93 11/13/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599626
Principal investigator 1 Astellas Pharma Inc $1,620.00 11/13/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599628
Principal investigator 1 Astellas Pharma Inc $358.35 11/13/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599630
Principal investigator 1 Astellas Pharma Inc $2,835.00 11/13/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599638
Principal investigator 1 Astellas Pharma Inc $1,215.00 11/13/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599644
Principal investigator 1 Astellas Pharma Inc $405.00 11/13/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599646
Principal investigator 1 AstraZeneca Pharmaceuticals LP $70,776.27 10/23/2024 Non-covered Recipient Entity
NEWYORK PRESBYTERIAN COLUMBIA UNIVERSITY IRVING MEDICAL CENTER
a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton No dispute reported 06/30/2026 1110839772
Principal investigator 1 Astellas Pharma Inc $360.15 10/03/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599570
Principal investigator 1 Astellas Pharma Inc $675.00 10/03/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599572
Principal investigator 1 Astellas Pharma Inc $675.00 10/03/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599574
Principal investigator 1 Astellas Pharma Inc $405.00 10/03/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599576
Principal investigator 1 Astellas Pharma Inc $3,297.90 10/03/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599578
Principal investigator 1 Daiichi Sankyo Inc. $0.85 09/04/2024 Non-covered Recipient Entity
Columbia University
DS7300-189 No dispute reported 06/30/2026 1086060044
Principal investigator 1 Daiichi Sankyo Inc. $1.95 09/04/2024 Non-covered Recipient Entity
Columbia University
DS7300-189 No dispute reported 06/30/2026 1086060046
Principal investigator 1 Daiichi Sankyo Inc. $6.60 09/04/2024 Non-covered Recipient Entity
Columbia University
DS7300-189 No dispute reported 06/30/2026 1086060048
Principal investigator 1 Daiichi Sankyo Inc. $14.90 09/04/2024 Non-covered Recipient Entity
Columbia University
DS7300-189 No dispute reported 06/30/2026 1086060050
Principal investigator 1 Daiichi Sankyo Inc. $37.35 09/04/2024 Non-covered Recipient Entity
Columbia University
DS7300-189 No dispute reported 06/30/2026 1086060052
Principal investigator 1 Daiichi Sankyo Inc. $46.50 09/04/2024 Non-covered Recipient Entity
Columbia University
DS7300-189 No dispute reported 06/30/2026 1086060054
Principal investigator 1 Daiichi Sankyo Inc. $46.50 09/04/2024 Non-covered Recipient Entity
Columbia University
DS7300-189 No dispute reported 06/30/2026 1086060056
Principal investigator 1 Daiichi Sankyo Inc. $46.50 09/04/2024 Non-covered Recipient Entity
Columbia University
DS7300-189 No dispute reported 06/30/2026 1086060058
Principal investigator 1 Daiichi Sankyo Inc. $46.50 09/04/2024 Non-covered Recipient Entity
Columbia University
DS7300-189 No dispute reported 06/30/2026 1086060060
Principal investigator 1 Daiichi Sankyo Inc. $46.50 09/04/2024 Non-covered Recipient Entity
Columbia University
DS7300-189 No dispute reported 06/30/2026 1086060062
Principal investigator 1 Daiichi Sankyo Inc. $46.50 09/04/2024 Non-covered Recipient Entity
Columbia University
DS7300-189 No dispute reported 06/30/2026 1086060064
Principal investigator 1 Daiichi Sankyo Inc. $46.50 09/04/2024 Non-covered Recipient Entity
Columbia University
DS7300-189 No dispute reported 06/30/2026 1086060066
Principal investigator 1 Daiichi Sankyo Inc. $46.50 09/04/2024 Non-covered Recipient Entity
Columbia University
DS7300-189 No dispute reported 06/30/2026 1086060068
Principal investigator 1 Daiichi Sankyo Inc. $46.50 09/04/2024 Non-covered Recipient Entity
Columbia University
DS7300-189 No dispute reported 06/30/2026 1086060070
Principal investigator 1 Daiichi Sankyo Inc. $46.50 09/04/2024 Non-covered Recipient Entity
Columbia University
DS7300-189 No dispute reported 06/30/2026 1086060072
Principal investigator 1 Daiichi Sankyo Inc. $46.50 09/04/2024 Non-covered Recipient Entity
Columbia University
DS7300-189 No dispute reported 06/30/2026 1086060074
Principal investigator 1 Daiichi Sankyo Inc. $46.50 09/04/2024 Non-covered Recipient Entity
Columbia University
DS7300-189 No dispute reported 06/30/2026 1086060076
Principal investigator 1 Daiichi Sankyo Inc. $46.50 09/04/2024 Non-covered Recipient Entity
Columbia University
DS7300-189 No dispute reported 06/30/2026 1086060078
Principal investigator 1 Daiichi Sankyo Inc. $46.50 09/04/2024 Non-covered Recipient Entity
Columbia University
DS7300-189 No dispute reported 06/30/2026 1086060080
Principal investigator 1 Daiichi Sankyo Inc. $50.15 09/04/2024 Non-covered Recipient Entity
Columbia University
DS7300-189 No dispute reported 06/30/2026 1086060082
Principal investigator 1 Daiichi Sankyo Inc. $51.55 09/04/2024 Non-covered Recipient Entity
Columbia University
DS7300-189 No dispute reported 06/30/2026 1086060084
Principal investigator 1 Daiichi Sankyo Inc. $62.55 09/04/2024 Non-covered Recipient Entity
Columbia University
DS7300-189 No dispute reported 06/30/2026 1086060086
Principal investigator 1 Daiichi Sankyo Inc. $86.30 09/04/2024 Non-covered Recipient Entity
Columbia University
DS7300-189 No dispute reported 06/30/2026 1086060088
Principal investigator 1 Daiichi Sankyo Inc. $112.05 09/04/2024 Non-covered Recipient Entity
Columbia University
DS7300-189 No dispute reported 06/30/2026 1086060090
Principal investigator 1 Daiichi Sankyo Inc. $112.05 09/04/2024 Non-covered Recipient Entity
Columbia University
DS7300-189 No dispute reported 06/30/2026 1086060092
Principal investigator 1 Daiichi Sankyo Inc. $237.25 09/04/2024 Non-covered Recipient Entity
Columbia University
DS7300-189 No dispute reported 06/30/2026 1086060094
Principal investigator 1 Astellas Pharma Inc $148.90 08/30/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599568
Principal investigator 1 Amgen Inc. $337,478.65 07/26/2024 Non-covered Recipient Entity
COLUMBIA UNIVERSITY IRVING MEDICAL CENTER
AMG 193 Combo with IDE397 MAT2A No dispute reported 06/30/2026 1096307759
Principal investigator 1 PFIZER INC. $42,453.75 07/03/2024 Non-covered Recipient Entity
COLUMBIA UNIVERSITY MEDICAL CENTER
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130956698
Principal investigator 1 Amgen Inc. $50,289.27 06/26/2024 Non-covered Recipient Entity
COLUMBIA UNIVERSITY IRVING MEDICAL CENTER
AMG 510 Ph1b Master Protocol 20190135 No dispute reported 06/30/2026 1096308243
Principal investigator 1 Astellas Pharma Inc $3,396.60 06/19/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599516
Principal investigator 1 Astellas Pharma Inc $3,285.90 06/19/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599518
Principal investigator 1 Astellas Pharma Inc $3,414.57 06/19/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599520
Principal investigator 1 Astellas Pharma Inc $3,396.60 06/19/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599522
Principal investigator 1 Astellas Pharma Inc $4,985.97 06/19/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599524
Principal investigator 1 Astellas Pharma Inc $4,200.27 06/19/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599526
Principal investigator 1 Astellas Pharma Inc $3,396.60 06/19/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599528
Principal investigator 1 Astellas Pharma Inc $3,285.90 06/19/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599530
Principal investigator 1 Astellas Pharma Inc $3,646.77 06/19/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599532
Principal investigator 1 Astellas Pharma Inc $3,646.77 06/19/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599534
Principal investigator 1 Astellas Pharma Inc $3,285.90 06/19/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599536
Principal investigator 1 Astellas Pharma Inc $3,285.90 06/19/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599538
Principal investigator 1 Astellas Pharma Inc $3,646.77 06/19/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599540
Principal investigator 1 Astellas Pharma Inc $3,396.60 06/19/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599542
Principal investigator 1 Astellas Pharma Inc $3,646.77 06/19/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599544
Principal investigator 1 Astellas Pharma Inc $5,253.16 06/19/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599546
Principal investigator 1 Astellas Pharma Inc $3,646.77 06/19/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599548
Principal investigator 1 Astellas Pharma Inc $3,396.60 06/19/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599550
Principal investigator 1 Astellas Pharma Inc $1,359.45 06/19/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599552
Principal investigator 1 Astellas Pharma Inc $3,396.60 06/19/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599554
Principal investigator 1 Astellas Pharma Inc $3,396.60 06/19/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599556
Principal investigator 1 Astellas Pharma Inc $3,285.90 06/19/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599558
Principal investigator 1 Astellas Pharma Inc $3,285.90 06/19/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599560
Principal investigator 1 Astellas Pharma Inc $3,646.77 06/19/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599562
Principal investigator 1 Astellas Pharma Inc $3,646.77 06/19/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599564
Principal investigator 1 Astellas Pharma Inc $3,285.90 06/19/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599566
Principal investigator 1 Astellas Pharma Inc $358.35 05/10/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599482
Principal investigator 1 Astellas Pharma Inc $405.00 05/10/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599484
Principal investigator 1 Astellas Pharma Inc $405.00 05/10/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599486
Principal investigator 1 Astellas Pharma Inc $3,297.90 05/10/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599488
Principal investigator 1 Astellas Pharma Inc $73.12 05/10/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599490
Principal investigator 1 Astellas Pharma Inc $810.00 05/10/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599492
Principal investigator 1 Astellas Pharma Inc $1,215.00 05/10/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599494
Principal investigator 1 Astellas Pharma Inc $3,297.90 05/10/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599496
Principal investigator 1 Astellas Pharma Inc $3,297.90 05/10/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599498
Principal investigator 1 Astellas Pharma Inc $405.00 05/10/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599500
Principal investigator 1 Astellas Pharma Inc $405.00 05/10/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599502
Principal investigator 1 Astellas Pharma Inc $405.00 05/10/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599506
Principal investigator 1 Astellas Pharma Inc $3,297.90 05/10/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599508
Principal investigator 1 Astellas Pharma Inc $405.00 05/10/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599510
Principal investigator 1 Astellas Pharma Inc $2,025.00 05/10/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599512
Principal investigator 1 Astellas Pharma Inc $3,297.90 05/10/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599514
Principal investigator 1 Astellas Pharma Inc $225.00 05/08/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599504
Principal investigator 1 Astellas Pharma Inc $4,200.27 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599426
Principal investigator 1 Astellas Pharma Inc $3,396.60 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599428
Principal investigator 1 Astellas Pharma Inc $3,285.90 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599430
Principal investigator 1 Astellas Pharma Inc $3,396.60 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599432
Principal investigator 1 Astellas Pharma Inc $2,647.35 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599434
Principal investigator 1 Astellas Pharma Inc $3,285.90 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599436
Principal investigator 1 Astellas Pharma Inc $1,972.35 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599438
Principal investigator 1 Astellas Pharma Inc $2,431.35 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599440
Principal investigator 1 Astellas Pharma Inc $1,972.35 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599442
Principal investigator 1 Astellas Pharma Inc $3,646.77 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599444
Principal investigator 1 Astellas Pharma Inc $4,985.97 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599446
Principal investigator 1 Astellas Pharma Inc $3,396.60 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599448
Principal investigator 1 Astellas Pharma Inc $3,396.60 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599450
Principal investigator 1 Astellas Pharma Inc $3,646.77 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599452
Principal investigator 1 Astellas Pharma Inc $3,396.60 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599454
Principal investigator 1 Astellas Pharma Inc $3,646.77 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599456
Principal investigator 1 Astellas Pharma Inc $3,396.60 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599458
Principal investigator 1 Astellas Pharma Inc $3,285.90 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599460
Principal investigator 1 Astellas Pharma Inc $3,285.90 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599462
Principal investigator 1 Astellas Pharma Inc $3,646.77 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599464
Principal investigator 1 Astellas Pharma Inc $3,396.60 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599466
Principal investigator 1 Astellas Pharma Inc $3,646.77 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599468
Principal investigator 1 Astellas Pharma Inc $5,253.16 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599470
Principal investigator 1 Astellas Pharma Inc $3,646.77 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599472
Principal investigator 1 Astellas Pharma Inc $3,396.60 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599474
Principal investigator 1 Astellas Pharma Inc $4,985.97 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599476
Principal investigator 1 Astellas Pharma Inc $3,646.77 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599478
Principal investigator 1 Astellas Pharma Inc $2,431.35 03/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599480
Principal investigator 1 Amgen Inc. $114.58 02/26/2024 Non-covered Recipient Entity
COLUMBIA UNIVERSITY IRVING MEDICAL CENTER
AMG 510 Ph1b Master Protocol 20190135 No dispute reported 06/30/2026 1096308245
Principal investigator 1 Amgen Inc. $30,529.60 02/20/2024 Non-covered Recipient Entity
COLUMBIA UNIVERSITY IRVING MEDICAL CENTER
AMG 193 Combo with IDE397 MAT2A No dispute reported 06/30/2026 1096307761
Principal investigator 1 Astellas Pharma Inc $3,396.60 01/29/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599419
Principal investigator 1 Astellas Pharma Inc $3,646.77 01/25/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599415
Principal investigator 1 Astellas Pharma Inc $3,285.90 01/22/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599413
Principal investigator 1 Astellas Pharma Inc $75.46 01/16/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599399
Principal investigator 1 Astellas Pharma Inc $3,297.90 01/16/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599401
Principal investigator 1 Astellas Pharma Inc $3,297.90 01/16/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599403
Principal investigator 1 Astellas Pharma Inc $1,500.00 01/16/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599405
Principal investigator 1 Astellas Pharma Inc $540.00 01/16/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599407
Principal investigator 1 Astellas Pharma Inc $3,375.00 01/16/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599409
Principal investigator 1 Astellas Pharma Inc $3,510.00 01/16/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599411
Principal investigator 1 Astellas Pharma Inc $169.38 01/16/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599417
Principal investigator 1 Astellas Pharma Inc $5,400.00 01/16/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599421
Principal investigator 1 Astellas Pharma Inc $6,075.00 01/16/2024 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128599423